JP6486349B2 - 薬物の送達 - Google Patents

薬物の送達 Download PDF

Info

Publication number
JP6486349B2
JP6486349B2 JP2016526933A JP2016526933A JP6486349B2 JP 6486349 B2 JP6486349 B2 JP 6486349B2 JP 2016526933 A JP2016526933 A JP 2016526933A JP 2016526933 A JP2016526933 A JP 2016526933A JP 6486349 B2 JP6486349 B2 JP 6486349B2
Authority
JP
Japan
Prior art keywords
substituted
group
unsubstituted
composition
lenk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016526933A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016539100A (ja
JP2016539100A5 (enExample
Inventor
ウチェグブ，イジェオマ
スチャツレイン，アンドレアス
ゴドフリー，リサ
ララトサ，カテリナ
イアンニテリ，アントニオ
Original Assignee
ナノメリクス リミテッド
ナノメリクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ナノメリクス リミテッド, ナノメリクス リミテッド filed Critical ナノメリクス リミテッド
Publication of JP2016539100A publication Critical patent/JP2016539100A/ja
Publication of JP2016539100A5 publication Critical patent/JP2016539100A5/ja
Application granted granted Critical
Publication of JP6486349B2 publication Critical patent/JP6486349B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016526933A 2013-11-04 2014-11-03 薬物の送達 Active JP6486349B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1319437.8A GB201319437D0 (en) 2013-11-04 2013-11-04 Delivery of drugs
GB1319437.8 2013-11-04
PCT/GB2014/053254 WO2015063510A1 (en) 2013-11-04 2014-11-03 Delivery of drugs

Publications (3)

Publication Number Publication Date
JP2016539100A JP2016539100A (ja) 2016-12-15
JP2016539100A5 JP2016539100A5 (enExample) 2017-11-24
JP6486349B2 true JP6486349B2 (ja) 2019-03-20

Family

ID=49767616

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016526933A Active JP6486349B2 (ja) 2013-11-04 2014-11-03 薬物の送達

Country Status (6)

Country Link
US (1) US10213474B2 (enExample)
EP (1) EP3065779B1 (enExample)
JP (1) JP6486349B2 (enExample)
CA (1) CA2928697C (enExample)
GB (1) GB201319437D0 (enExample)
WO (1) WO2015063510A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202007703D0 (en) * 2020-05-22 2020-07-08 Nanomerics Ltd Amphiphilic carbohydrate compounds
CA3192515A1 (en) * 2020-08-24 2022-03-03 Nanomerics Limited Viral inhibitors
US20250009676A1 (en) * 2021-10-06 2025-01-09 Purdue Pharma L.P. Compositions and methods for levodopa delivery

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763393A (en) * 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
GB0221941D0 (en) 2002-09-20 2002-10-30 Univ Strathclyde Polysoaps
GB0315632D0 (en) * 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
US8187570B1 (en) * 2005-01-04 2012-05-29 Gp Medical, Inc. Nanoparticles for protein drug delivery
GB0615834D0 (en) 2006-08-09 2006-09-20 Univ Glasgow Polymeric micellar clusters and their uses in formulating drugs
JP2009252275A (ja) * 2008-04-03 2009-10-29 Nec Electronics Corp 半導体記憶装置
TWI437007B (zh) * 2008-07-24 2014-05-11 Food Industry Res & Dev Inst 於水相中製備幾丁聚醣奈米顆粒之方法
GB0903559D0 (en) * 2009-03-02 2009-04-08 Univ London Pharmacy Oral delivery of hydrophilic drugs to the brain
WO2012039979A2 (en) * 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
EP3269372B1 (en) * 2012-01-19 2019-06-12 Hybrid Medical, LLC Topical therapeutic formulations

Also Published As

Publication number Publication date
GB201319437D0 (en) 2013-12-18
WO2015063510A1 (en) 2015-05-07
CA2928697A1 (en) 2015-05-07
US10213474B2 (en) 2019-02-26
US20160279189A1 (en) 2016-09-29
EP3065779A1 (en) 2016-09-14
EP3065779B1 (en) 2019-06-26
JP2016539100A (ja) 2016-12-15
CA2928697C (en) 2022-01-25

Similar Documents

Publication Publication Date Title
JP5469458B2 (ja) 高分子ミセルクラスタ及びそれらの薬剤への使用
Liu et al. Intranasal administration of carbamazepine-loaded carboxymethyl chitosan nanoparticles for drug delivery to the brain
Guan et al. N-trimethyl chitosan nanoparticle-encapsulated lactosyl-norcantharidin for liver cancer therapy with high targeting efficacy
Elsayed et al. Formulation and characterization of an oily-based system for oral delivery of insulin
US10561733B2 (en) Process for producing nanoparticles laden with active ingredient
Jena et al. Polymeric micelles of amphiphilic graft copolymer of α-tocopherol succinate-g-carboxymethyl chitosan for tamoxifen delivery: Synthesis, characterization and in vivo pharmacokinetic study
Zheng et al. Galactosylated chitosan nanoparticles for hepatocyte-targeted delivery of oridonin
Losada-Barreiro et al. Carrier systems for advanced drug delivery: Improving drug solubility/bioavailability and administration routes
Patil et al. Orally fast-dissolving drug delivery systems for pediatrics: Nanofibrous oral strips from isoniazid/cyclodextrin inclusion complexes
Gao et al. Effect of glyceryl monocaprylate–modified chitosan on the intranasal absorption of insulin in rats
JP6486349B2 (ja) 薬物の送達
WO2010009075A1 (en) Methods and compositions comprising crystalline nanoparticles of hydrophobic compounds
CN108191995A (zh) 一种还原敏感的两亲性多糖衍生物及其制备方法和用途
Silva-Carvalho et al. Covalent conjugation of amphotericin B to hyaluronic acid: an injectable water-soluble conjugate with reduced toxicity and anti-leishmanial potential
WO2009052491A2 (en) Fenoldopam formulations and prodrug derivatives
EP2042166A1 (en) Nanocapsules for oral delivery of proteins
Luan et al. Mannosamine-Engineered Nanoparticles for Precision Rifapentine Delivery to Macrophages: Advancing Targeted Therapy Against Mycobacterium Tuberculosis
Ren et al. Novel Supramolecular Nanoparticles Modified with Phosphatidylcholine Improve the Bioavailability of Fisetin and Alleviate Alcoholism through Antioxidant and Antiinflammatory Effects
CN101217946A (zh) 水不溶性的或低水溶性药物在脂质化糖胺聚糖颗粒中的制剂和它们的诊断和治疗用途
KR20120048811A (ko) 아나스트로졸 함유 고분자 미립구를 유효성분으로 포함하는 약학적 조성물
CN115916142A (zh) 偶联萜烯缀合物
EP1693051B1 (en) Composition containing chitosan for sustained drug release
Ha et al. Enhanced oral bioavailability of resveratrol by using neutralized Eudragit E solid dispersion prepared via spray drying. Antioxidants 2021; 10: 90
EP4559483A1 (en) Hyaluronic acid derivative drug composition and drug composition
Hobson Prodrugs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190122

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190219

R150 Certificate of patent or registration of utility model

Ref document number: 6486349

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250